Cargando…

Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands

SIMPLE SUMMARY: Acinic cell carcinoma is a rare disease treated usually by surgery. The role of radiotherapy is controversially discussed. In this retrospective analysis based on 15 patients undergoing postoperative or definitive radiotherapy (intensity-modulated radiotherapy, IMRT) with carbon ion...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Maximilian P., Held, Thomas, Lang, Kristin, Herfarth, Klaus, Hörner-Rieber, Juliane, Harrabi, Semi B., Moratin, Julius, Freudlsperger, Christian, Zaoui, Karim, Debus, Jürgen, Adeberg, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795372/
https://www.ncbi.nlm.nih.gov/pubmed/33401730
http://dx.doi.org/10.3390/cancers13010124
_version_ 1783634429570187264
author Schmid, Maximilian P.
Held, Thomas
Lang, Kristin
Herfarth, Klaus
Hörner-Rieber, Juliane
Harrabi, Semi B.
Moratin, Julius
Freudlsperger, Christian
Zaoui, Karim
Debus, Jürgen
Adeberg, Sebastian
author_facet Schmid, Maximilian P.
Held, Thomas
Lang, Kristin
Herfarth, Klaus
Hörner-Rieber, Juliane
Harrabi, Semi B.
Moratin, Julius
Freudlsperger, Christian
Zaoui, Karim
Debus, Jürgen
Adeberg, Sebastian
author_sort Schmid, Maximilian P.
collection PubMed
description SIMPLE SUMMARY: Acinic cell carcinoma is a rare disease treated usually by surgery. The role of radiotherapy is controversially discussed. In this retrospective analysis based on 15 patients undergoing postoperative or definitive radiotherapy (intensity-modulated radiotherapy, IMRT) with carbon ion radiotherapy boost leads to excellent results after R1-resection, and is a promising treatment modality in inoperable patients. G1-2 xerostomia, dysgeusia, and trismus were the main reported morbidity symptoms after radiotherapy. Confirmation of the results with larger patient cohorts is needed. ABSTRACT: Aim: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. Materials and Methods: all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18–24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50–54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results: fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. Conclusion: In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients.
format Online
Article
Text
id pubmed-7795372
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77953722021-01-10 Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands Schmid, Maximilian P. Held, Thomas Lang, Kristin Herfarth, Klaus Hörner-Rieber, Juliane Harrabi, Semi B. Moratin, Julius Freudlsperger, Christian Zaoui, Karim Debus, Jürgen Adeberg, Sebastian Cancers (Basel) Article SIMPLE SUMMARY: Acinic cell carcinoma is a rare disease treated usually by surgery. The role of radiotherapy is controversially discussed. In this retrospective analysis based on 15 patients undergoing postoperative or definitive radiotherapy (intensity-modulated radiotherapy, IMRT) with carbon ion radiotherapy boost leads to excellent results after R1-resection, and is a promising treatment modality in inoperable patients. G1-2 xerostomia, dysgeusia, and trismus were the main reported morbidity symptoms after radiotherapy. Confirmation of the results with larger patient cohorts is needed. ABSTRACT: Aim: to report clinical outcome in patients with acinic cell carcinoma of the salivary glands treated with intensity-modulated radiotherapy (IMRT) and carbon ion radiotherapy (CIRT) boost. Materials and Methods: all patients with acinic cell carcinoma of the salivary glands treated at the Heidelberg Ion-Beam Therapy Center were considered for this retrospective analysis. All patients received a CIRT boost with 18–24 Gy radiobiologic effectiveness (RBE)-weighted dose in 3 Gy RBE-weighted dose per fraction followed by IMRT, with 50–54 Gy in 2 Gy per fraction. Disease outcome was evaluated for local (LR), nodal (NR), distant recurrence (DR), and disease-free (DFS) and overall survival (OS). Morbidity was scored based on Common Terminology Criteria for Adverse Events (CTCAE) version 5. Descriptive statistics and the Kaplan-Meier method were used for analysis. Results: fifteen patients were available for analysis. Median follow-up after radiotherapy was 43 months. Six patients were treated for primary disease and nine for recurrent disease. Eight patients were treated with radiotherapy for macroscopic disease. Disease recurrence was observed in four patients: 1 LR, 2 NR, and 2 DR; 5-year local control, DFS, and OS were 80%, 52%, and 80%, respectively. No radiotherapy-related G3-5 morbidity was observed. Conclusion: In acinic cell carcinoma, IMRT with carbon ion radiotherapy boost leads to excellent results after R1-resection and is a promising treatment modality for definitive treatment in inoperable patients. MDPI 2021-01-02 /pmc/articles/PMC7795372/ /pubmed/33401730 http://dx.doi.org/10.3390/cancers13010124 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schmid, Maximilian P.
Held, Thomas
Lang, Kristin
Herfarth, Klaus
Hörner-Rieber, Juliane
Harrabi, Semi B.
Moratin, Julius
Freudlsperger, Christian
Zaoui, Karim
Debus, Jürgen
Adeberg, Sebastian
Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
title Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
title_full Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
title_fullStr Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
title_full_unstemmed Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
title_short Intensity Modulated Radiotherapy with Carbon Ion Radiotherapy Boost for Acinic Cell Carcinoma of the Salivary Glands
title_sort intensity modulated radiotherapy with carbon ion radiotherapy boost for acinic cell carcinoma of the salivary glands
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795372/
https://www.ncbi.nlm.nih.gov/pubmed/33401730
http://dx.doi.org/10.3390/cancers13010124
work_keys_str_mv AT schmidmaximilianp intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT heldthomas intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT langkristin intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT herfarthklaus intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT hornerrieberjuliane intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT harrabisemib intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT moratinjulius intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT freudlspergerchristian intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT zaouikarim intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT debusjurgen intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands
AT adebergsebastian intensitymodulatedradiotherapywithcarbonionradiotherapyboostforaciniccellcarcinomaofthesalivaryglands